Wellcome and the Gates Foundation to fund late-stage development of a TB vaccine candidate

Wellcome and the Bill & Melinda Gates Foundation announce US$550 million funding to advance a TB vaccine candidate, M72/AS01E, through a Phase III clinical trial that could be the first in 100 years if proven effective.